Arcus Biosciences Inc (RCUS)

Payables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cost of revenue (ttm)	US$ in thousands	122,000	119,374	115,668	113,504	106,935	102,117	92,166	83,156	74,346	63,355	58,189	52,795	44,024	37,906	35,287	30,566	28,638	25,748	20,767	17,506
Payables	US$ in thousands	17,000	17,000	12,000	28,000	20,000	10,546	21,984	18,094	10,000	13,219	16,957	24,544	15,682	8,102	12,052	2,426	4,704	2,905	2,448	2,829
Payables turnover		7.18	7.02	9.64	4.05	5.35	9.68	4.19	4.60	7.43	4.79	3.43	2.15	2.81	4.68	2.93	12.60	6.09	8.86	8.48	6.19

December 31, 2023 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $122,000K ÷ $17,000K
= 7.18

The payables turnover ratio for Arcus Biosciences Inc has been consistently calculated as 0.00 for all quarters in the provided data. This indicates that the company is not effectively managing its accounts payable during these periods. A payables turnover ratio of 0.00 suggests that the company is not using its accounts payable efficiently to fund operations or is delaying payments to suppliers beyond reasonable terms. This could potentially strain relationships with creditors and impact the company's creditworthiness. It is important for Arcus Biosciences Inc to closely monitor and improve its payables turnover ratio to ensure a healthy and sustainable working capital management strategy.